Luminex Corporation LMNX and One Lambda, Inc. have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen typing and antibody screening for the organ transplantation market.
Begun in 2000, their dedicated collaboration has resulted in the creation of innovative products that have made pre- and post-transplant diagnostics faster, and more cost-efficient.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in